An Open-Label, Non-Randomized Clinical Study to Evaluate Pharmacokinetic (PK) Profiles, Safety, and Tolerability of Abexinostat Monotherapy in Patients With Non-Hodgkin's Lymphoma Who Have Failed Standard of Care
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Abexinostat (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Xynomic Pharmaceuticals
Most Recent Events
- 10 Apr 2025 Planned End Date changed from 30 Jun 2024 to 30 Nov 2025.
- 22 Jan 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 22 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 29 Feb 2024.